Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Acquisition of gene therapy HMR59, significantly expands Janssen's eye disease portfolio and strengthens its gene therapy capabilities.
Lead Product(s): HMR59
Therapeutic Area: Ophthalmology Product Name: HMR59
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 02, 2020